PMID- 15476255
OWN - NLM
STAT- MEDLINE
DCOM- 20041130
LR  - 20061115
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 50
IP  - 10
DP  - 2004 Oct
TI  - Antigen-specific immunomodulation of collagen-induced arthritis with tumor 
      necrosis factor-stimulated dendritic cells.
PG  - 3354-64
AB  - OBJECTIVE: Dendritic cells (DCs) are crucial for the initiation of T cell 
      immunity and therefore play an important role in the initiation and regulation of 
      immune responses in arthritis. Full mobilization of effector T cells depends on 
      the proper maturation of DCs. Current evidence indicates that the type of T cell 
      response induced is crucially dependent on the activation status of the DCs. In 
      this study, we explored the immunologic effects of differentially matured DCs on 
      the development of collagen-induced arthritis (CIA). METHODS: Bone marrow-derived 
      DCs were cultured in the presence of granulocyte-macrophage colony-stimulating 
      factor (GM-CSF). Before immunization with bovine type II collagen (CII) protein, 
      mice were repeatedly injected with DCs that had been pulsed with CII. Immature, 
      semimature, or fully mature DCs were injected. Mice were boosted on day 21 after 
      CII immunization, and the disease course was monitored. RESULTS: While 
      vaccination with immature or lipopolysaccharide-activated DCs had no significant 
      effect on the disease course, administration of antigen-loaded, tumor necrosis 
      factor (TNF)-modulated DCs propagated in GM-CSF with or without interleukin-4 
      resulted in a delayed onset of arthritis and a lower clinical score. The response 
      was antigen-specific, since TNF-treated DCs pulsed with a control antigen did not 
      modify the disease course. A specific decrease in the collagen-specific 
      "Th1-associated" IgG2a response was observed, whereas IgG1 titers were 
      unaffected. CONCLUSION: CIA can be prevented through vaccination with TNF-matured 
      DCs in an antigen-specific manner. These findings provide a rationale for 
      immunotherapy using DCs in rheumatoid arthritis.
CI  - Copyright 2004 American College of Rheumatology
FAU - van Duivenvoorde, Leonie M
AU  - van Duivenvoorde LM
AD  - Leiden University Medical Centre, Leiden, The Netherlands.
FAU - Louis-Plence, Pascale
AU  - Louis-Plence P
FAU - Apparailly, Florence
AU  - Apparailly F
FAU - van der Voort, Ellen I H
AU  - van der Voort EI
FAU - Huizinga, Tom W J
AU  - Huizinga TW
FAU - Jorgensen, Christian
AU  - Jorgensen C
FAU - Toes, Rene E M
AU  - Toes RE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Animals
MH  - Arthritis, Experimental/chemically induced/*immunology/prevention & control
MH  - Cells, Cultured
MH  - Collagen
MH  - Dendritic Cells/*immunology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Immunization
MH  - Interleukin-4/pharmacology
MH  - Mice
MH  - Mice, Inbred DBA
MH  - T-Lymphocytes, Regulatory/immunology
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2004/10/12 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/10/12 09:00
PHST- 2004/10/12 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/12 09:00 [entrez]
AID - 10.1002/art.20513 [doi]
PST - ppublish
SO  - Arthritis Rheum. 2004 Oct;50(10):3354-64. doi: 10.1002/art.20513.